01Core principlesThe concepts and mechanisms needed to understand the subject.
Staging is a time-stamped description of disease distribution. Clinical staging integrates what can be established before definitive treatment: tumour size and skin or chest-wall involvement, regional nodal basins, biopsy-proven histology and any distant lesions. It guides neoadjuvant treatment, surgery and radiotherapy. It should state the evidence behind each component, because a suspicious node on imaging is not equivalent to a pathologically proven metastasis.
Pathological staging supplies measured invasion, nodal deposit size and other definitive features after surgery. Neoadjuvant therapy changes the notation: baseline cTNM is preserved, while ypTNM describes residual viable tumour after treatment. A complete response in the specimen is clinically valuable but does not mean the person never had cancer. Receptor status, grade and genomic profiling inform prognosis and treatment while remaining separate from anatomical TNM.
Key points
- TNM separates the primary tumour, regional lymph nodes and distant metastases. Anatomical stage and prognostic biology are related but answer different questions.
- Clinical stage uses examination, breast and axillary imaging, needle pathology and indicated systemic staging before treatment; it remains the baseline after neoadjuvant therapy.
- Pathological stage uses the resection and nodal specimens after primary surgery. After neoadjuvant treatment, the yp prefix records residual disease and response rather than erasing pretreatment burden.
- Measure invasive tumour for T stage; an extensive in-situ component affects local surgery but does not make the invasive T category equal to the whole calcification span.
- Every patient with early or locally advanced invasive cancer needs pretreatment axillary ultrasound, with ultrasound-guided sampling of morphologically abnormal nodes.
- Distant imaging is driven by symptoms, locally advanced burden or treatment consequences; indeterminate lesions should be characterised before automatically assigning stage IV disease.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Record invasive size, multifocal distribution and direct skin or chest-wall involvement; oedema, ulceration and inflammatory phenotype have staging consequences beyond diameter.
Axillary levels, internal mammary and supraclavicular nodes are regional. Morphology, fixation and pathology establish more than simple palpated size.
Persistent focal bone pain, neurological deficit, respiratory symptoms, abnormal liver tests or systemic decline may justify metastatic assessment before curative treatment.
Grade, ER, PR and HER2 affect recurrence risk and therapy but should not be substituted for documented tumour, node and metastasis categories.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Bilateral diagnostic breast imaging - Why
- Define the index tumour, multifocality and contralateral abnormalities for local staging.
- Interpretation and limitations
- Mammography and ultrasound measurements must be correlated with examination and biopsy. MRI is selective when conventional extent is unclear or density or lobular histology creates a defined uncertainty.
- 02
Axillary ultrasound and needle sampling - Why
- Assess regional nodes before treatment and provide pathological confirmation of abnormal morphology.
- Interpretation and limitations
- A positive node establishes involvement. Normal ultrasound or an adequately targeted negative sample leads to sentinel staging if primary surgery is planned.
- 03
Systemic staging imaging - Why
- Identify visceral or skeletal metastases when clinical stage, symptoms or planned treatment make the result consequential.
- Interpretation and limitations
- CT, MRI, bone imaging or PET-CT is selected by the clinical question. Equivocal abnormalities require comparison, targeted imaging or biopsy before a curative plan is abandoned.
- 04
Definitive surgical pathology - Why
- Measure residual invasive tumour, margins and nodal deposits and provide pTNM or ypTNM.
- Interpretation and limitations
- Pathological size refers to invasion; treatment effect and scattered residual foci need specialist measurement rules. Include number of nodes examined and involved.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: pretreatment stageConstruct a traceable cTNM baselineA 52-year-old has a 38 mm invasive carcinoma on imaging, a suspicious axillary node and no distant symptoms before treatment.+
- 1In this illustrative case, examination finds no skin or chest-wall involvement. Mammography and ultrasound agree on a 38 mm invasive target, while core biopsy confirms ER-positive, HER2-negative carcinoma and sampling proves metastasis in the suspicious ipsilateral axillary node. These findings establish the clinical T2 size category and regional disease before treatment; the nodal category is assigned from the full clinical assessment, not from a presumed surgical node count.
- 2The multidisciplinary team requests systemic staging because the proven regional burden could change the treatment plan. CECT shows no distant metastases, so the distant assessment is recorded clinically as cM0. The report identifies the source and date of each finding rather than using absence of symptoms alone as proof of absence of spread.
- 3After discussion of tumour biology, breast size, local-treatment feasibility and systemic options, the patient chooses the recommended primary-surgery pathway. Breast conservation and the planned axillary clearance are completed; the operative and specimen records retain the pretreatment imaging and biopsy evidence.
- 4Excision measures 35 mm of invasive carcinoma with clear radial margins. One of twelve axillary nodes contains a 4 mm deposit. The postoperative record therefore adds pT2 and pN1a to the existing clinical distant assessment; it does not invent pM0 or silently replace the original clinical record.
- 5At postoperative review, pathology, imaging and the node count are reconciled and the completed record is used to plan adjuvant treatment. The patient explains back that the clinical and pathological measurements describe different assessments, and that future treatment response would be recorded separately rather than erasing the baseline.
02Postoperative stage pathwayTranslate specimens into pTNMPrimary breast conservation and sentinel-node biopsy are complete without prior systemic therapy.+
- 1Confirm the pathology report measures invasive size separately from surrounding DCIS and records grade, lymphovascular invasion and radial margins.
- 2Record sentinel-node deposit category, number involved and number examined rather than writing only “node positive”.
- 3Combine pT and pN with the established absence or presence of distant disease and current receptor biology at postoperative review.
- 4Use the completed stage to finalise radiotherapy and systemic treatment, and provide the patient with a comprehensible written summary.
03Neoadjuvant response pathwayPreserve baseline and record residual burdenA node-positive HER2-positive tumour becomes impalpable after systemic therapy and surgery shows no residual invasive cancer.+
- 1Retain the original clinical tumour and node stage in the record, including biopsy proof and pretreatment imaging.
- 2Ensure the surgical specimen and clipped target are adequately sampled and the previously involved nodal basin is evaluated by the planned method.
- 3Report residual disease with yp notation and pathological response rather than replacing the baseline history with “stage zero”.
- 4Use both baseline burden and response to guide postoperative HER2-directed therapy, radiotherapy and prognosis discussion.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- At every multidisciplinary transition, display the baseline cTNM, evidence for nodal status, receptor profile and any unresolved distant lesion in one auditable summary.
- After neoadjuvant treatment, compare examination and imaging with baseline while recognising that imaging complete response does not prove pathological complete response.
- After surgery, reconcile specimen measurements, margin status and nodal deposit size with the operation performed before assigning pTNM or ypTNM.
- During follow-up, investigate new symptoms according to clinical concern; a stable historical stage neither proves nor excludes recurrence.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Stage belongs to a time point
Clinical, pathological and post-neoadjuvant stages can all be correct for the same patient because they record different evidence and treatment moments.
Node suspicion is not proof
Ultrasound morphology selects nodes for sampling; pathology distinguishes proven metastasis from reactive or indeterminate enlargement.
DCIS span differs from invasive size
A broad calcification field can drive mastectomy while the invasive component remains small for T categorisation.
Response adds prognostic information
Pathological response after neoadjuvant therapy influences subsequent treatment but must be interpreted beside original stage and tumour biology.
07Common pitfallsFrequent interpretation and management errors.
- 01
Replacing baseline stage with the post-treatment stage loses the disease burden that justified neoadjuvant therapy and radiotherapy.
- 02
Calling an indeterminate liver or bone lesion metastatic without confirmation can incorrectly remove curative-intent options.
- 03
Using the entire DCIS calcification span as invasive tumour size overstates anatomical T category.
- 04
Writing “nodes positive” without deposit size, number involved and method obscures the evidence needed for axillary and radiotherapy decisions.